FDA Brief

Warning letters Drugs

FDA warning letter to

Unipack LLC

High riskIssued Dec 19, 2025Posted Dec 30, 2025Center for Drug Evaluation and Research (CDER)

FDA says Unipack LLC released suppositories without adequate out-of-specification investigations, complete lab records, and required USP testing.

What happened

FDA inspected Unipack LLC's drug manufacturing facility from June 11 to June 30, 2025. FDA found inadequate investigations of out-of-specification (OOS) results and unknown peaks in lab test charts, incomplete and non-contemporaneous laboratory records, weak electronic data controls, and release specifications missing USP-required tests for suppositories.

What FDA found

  1. Unipack did not thoroughly investigate out-of-specification (OOS) results and unknown peaks, invalidated OOS results without identified lab error, and released batches without root cause or corrective action.

    21 CFR 211.192
  2. Laboratory records were incomplete or not recorded at the time of testing, including undated sample preparations and high-performance liquid chromatography (HPLC) injections with no processed results or notebook entry.

    21 CFR 211.194(a)
  3. Analysts had administrator rights that allowed alteration or deletion of lab data and files, and deleted-system errors were not assessed.

    21 CFR 211.194(a)
  4. Analysts manually adjusted HPLC peak integration without scientific justification or procedural controls.

    21 CFR 211.194(a)
  5. Release specifications for suppositories omitted USP-required identification and assay tests, and multiple batches were distributed since March 2022 without those tests.

    21 CFR 211.160(b)

What FDA wants

FDA tells Unipack to correct the violations promptly and respond in writing within 15 working days with corrective actions and plans, including independent assessments and remediation for its investigations, corrective and preventive action (CAPA) program, laboratory controls, and data integrity.

Who should pay attention

  • companies that buy or distribute Unipack-made drugs
  • contract manufacturers and testing labs with similar data controls
  • quality units overseeing suppository products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk